The 9 largest diabetes technology companies in the world
Aug 21, 2024 · 1. Abbott Diabetes Care — 2023 revenue: $5.761B. Abbott, one of the world’s largest medtech companies in a broader sense, takes the top spot in diabetes, too. The company’s Diabetes Care unit brought in more than $2 billion more than any other company on this list. With its Diabetes Care unit located in Alameda, California, Abbott ...
Dexcom announces direct-to-watch feature for G7 CGM
Mar 5, 2024 · The ONE+ system, featuring a sensor, reader, smartphone, smartwatch and applicator. [Image courtesy of Dexcom] Dexcom (Nasdaq:DXCM) announced today that it introduced a direct-to-Apple-Watch feature for its G7 continuous glucose monitor (CGM) users. The company plans a phased launch for all G7 iOS users everywhere by the end of the second quarter of this year.
Insulet fully launches Omnipod 5 with Dexcom G7 in the U.S.
Jun 20, 2024 · Omnipod 5, the first FDA-cleared tubeless automated insulin delivery system, communicates with a CGM. It proactively corrects for highs and protects against lows with insulin dosing. The waterproof device features mobile app control for ease of use. Acton, Massachusetts-based Insulet began a limited rollout of Omnipod 5 with G7 earlier this year.
Insulet data shows Omnipod 5's superiority to regular pump therapy
Mar 8, 2024 · Results demonstrated significantly lower mean glucose and time above 180 mg/dL in the Omnipod 5 group. That group also spent significantly less time below 70 mg/dL. Mean time decreased from 1.66% to 1.18% with Omnipod 5, compared to an increase from 1.66% to 1.75% in the control group. Time below 54 mg/dL proved non-inferior between groups.
Roche Diabetes unveils new CGM tech with predictive AI
Mar 7, 2024 · This is a screenshot from a video demonstrating the features of the new Roche Accu-Chek SmartGuide CGM at ATTD 2024. Roche today gave a presentation debuting its first continuous glucose monitor (CGM) offering that utilizes predictive AI.. The company unveiled its Accu-Chek SmartGuide in an event at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Florence, Italy.
Senseonics, Ascensia launch Eversense 365 year-long CGM
Oct 1, 2024 · Brian Hansen, Ascensia and Senseonics’ president of CGM, explained the company’s future plans at ADA 2024. Senseonics and Ascensia plan to launch the CGM alongside a new Payment Assistance and Simple Savings (PASS) program. Eligible individuals can pay as little as $199 out of pocket for one year of continuous glucose monitoring.
Qnovia wins FDA IND for nicotine inhaler for smoking cessation
Oct 2, 2024 · Qnovia’s nicotine replacement therapy device. [Image courtesy of Qnovia] Qnovia announced that the FDA cleared its investigational new drug (IND) application for the RespiRx smoking cessation inhaler (QN-01). RespiRx, a drug-device combination product, offers inhalable nicotine replacement therapy (NRT) to assist in the quitting of smoking.
The company behind Narcan looks toward a treatment for fentanyl ...
Mar 13, 2018 · A nasal spray designed to reverse opioid overdoses called Narcan has become a life-saving tool used by police departments and communities around the country. Now, the company that created Narcan – Opiant Pharmaceuticals (NSDQ: OPNT) – is hoping that its latest drug-device combination can help people who are overdosing from fentanyl.
FDA clears iPhone app for the Insulet Omnipod 5 - Drug Delivery …
Oct 23, 2023 · Insulet’s Omnipod 5 with the Dexcom G6 CGM. [Image from Insulet] Insulet (Nasdaq:PODD) announced today that the FDA granted 510(k) clearance for its Omnipod 5 App for iPhone. Clearance makes Insulet the only company offering a tubeless, automated insulin delivery (AID) system with full control from a compatible Android and iOS smartphone.
Court says SiBio can't sell CGM in some countries in Abbott IP spat
Jul 1, 2024 · Abbott filed them against China-based SiBionics (SiBio) and its sales partner Umedwings at the Unified Patent Court. The company also has ongoing litigation in other European countries, including the UK, Italy and Spain. According to JUVE-Patent, Abbott aims to prevent SiBio from entering the European market with its CGM technology.